SPARC-like 1/SPARCL1 Antibody [Unconjugated]

Western blot shows lysates of human lung tissue. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human SPARC-like 1/ SPARCL1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2728) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for SPARC-like 1/SPARCL1 at approximately 130 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

SPARC-like 1/SPARCL1 was detected in immersion fixed paraffin-embedded sections of human brain using Goat Anti-Human SPARC-like 1/SPARCL1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2728) at 15 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to neurons. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

HL‑60 human acute promyelocytic leukemia cell line was stained with Goat Anti-Human SPARC‑like 1/SPARCL1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2728, filled histogram) or control antibody (Catalog # AB-108-C, open histogram), followed by Phycoerythrin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0107). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin.

• Reactivity: Hu
• Applications: WB, IHC, CyTOF-ready, Flow
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

SPARC-like 1/SPARCL1 Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human SPARC-like 1/SPARCL1 (R&D Systems, Catalog # 2728-SL)
  Ile17-Phe664
  Accession # Q8N4S1
• Specificity: Detects human SPARC-like 1/SPARCL1 in direct ELISAs and Western blots. In direct ELISAs, less than 15% cross-reactivity with recombinant mouse (rm) SPARC-like 1/SPARCL1 is observed and less than 1% cross-reactivity with recombinant human SPARC is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: SPARCL1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Immunohistochemistry 5-15 ug/mL
  • Intracellular Staining by Flow Cytometry 2.5 ug/10^6 cells
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for SPARC-like 1/SPARCL1 Antibody [Unconjugated]

• Hevin
• High endothelial venule protein
• MAST 9
• MAST9
• PIG33
• proliferation-inducing protein 33
• SC1
• SPARC like 1
• SPARCL1
• SPARC-like 1 (hevin)
• SPARC-like 1 (mast9, hevin)
• SPARC-like 1
• SPARC-like protein 1

Background

SPARCL1 (Secreted Protein, Acidic and Rich in Cysteines-like 1), also known as hevin, SC1 or MAST9, is a member of the SPARC family of extracellular glycoproteins (1, 2). SPARCL1 is an anti-adhesive protein that is widely expressed in tissues such as brain, heart, lung, muscle and kidney, but not liver (3, 4). Human SPARCL1 contains a 16 amino acid (aa) signal sequence and a 648 aa mature region with four domains: a 416 aa N-terminal acidic region, a 23 aa follistatin-like domain, a 55 aa kazal-like segment and a 48 aa EF-hand/calcium-binding domain (3, 4). SPARCL1 is predicted at 75 kDa, but migrates at ~130 kDa, which has been explained either by disulfide-linked homodimerization or by glycosylation and high acidity (3-5). Some truncated forms have been reported. In mouse, a 55 kDa C-terminal fragment is the only form in kidney and represents a portion of SPARCL1 in other tissues (6). In humans, a 25 kDa form is increased in liver tumors that are encapsulated, while the full-length form is downregulated in many epithelial cell-derived tumors (7, 8). SPARCL1 inhibits adhesion and spreading on a variety of substrates (5, 9). It is thought to cause antiadhesive signaling that terminates neuronal migration, consistent with production by glial and neuronal cells during development or in response to trauma (10). In tonsillar high endothelial venules (HEV), SPARCL1 may induce endothelial cell dissociation, promoting extravasation (3). SPARCL1 binds collagen; in mice, deletion causes dermal collagen fibrils that are smaller in diameter and deficient in decorin (6, 11). Human mature SPARCL1 shares 67%, 69%, 78%, 76%, 72%, and 72% aa identity with mouse, rat, equine, canine, porcine and bovine SPARCL1, respectively. The follistatin-like, kazal-like and calcium-binding domains of SPARCL1 show 61% aa identity with corresponding regions of SPARC.

1. Framson, P.E. and E.H. Sage (2004) J. Cell. Biochem. 92:679.
2. Sullivan, M.M. and E.H. Sage (2004) Int. J. Biochem. Cell Biol. 36:991.
3. Girard, J.P. and T.A. Springer (1995) Immunity 2:113.
4. Bendik, I. et al. (1998) Cancer Res. 58:626.
5. Brekken, R.A. et al. (2004) J. Histochem. Cytochem. 52:735.
6. Hambrock, H.O. et al. (2003) J. Biol. Chem. 278:11351.
7. Lau, C.P. et al. (2006) J. Pathol. 210:469.
8. Isler, S.G. et al. (2001) Int. J. Oncol. 18:521.
9. Girard, J.P. and T.A. Springer (1996) J. Biol. Chem. 271:4511.
10. Gongidi, V. et al. (2004) Neuron 41:57.
11. Sullivan, M.M. et al. (2006) J. Biol. Chem. 281:27621.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for SPARC-like 1/SPARCL1 Antibody (AF2728)(13)

Publications using AF2728

• Wang, L;Wang, C;Moriano, JA;Chen, S;Zuo, G;Cebrián-Silla, A;Zhang, S;Mukhtar, T;Wang, S;Song, M;de Oliveira, LG;Bi, Q;Augustin, JJ;Ge, X;Paredes, MF;Huang, EJ;Alvarez-Buylla, A;Duan, X;Li, J;Kriegstein, AR; Molecular and cellular dynamics of the developing human neocortex at single-cell resolution bioRxiv : the preprint server for biology 2024-08-04 [PMID: 39131371] (Immunohistochemistry, Immunocytochemistry, Human)
• Sachdeva, MM;Lee, Y;Unlu, EK;Koseoglu, ND;Cha, E;Wang, J;Prescott, CR;Eghrari, AO;Na, CH; Tandem Mass Tag LC-MS/MS of Aqueous Humor From Individuals With Type 2 Diabetes Without Retinopathy Reveals Early Dysregulation of Synaptic Proteins Investigative ophthalmology & visual science 2024-03-05 [PMID: 38470329] (Western Blot, Human)
• Y Fu, M Yang, H Yu, Y Wang, X Wu, J Yong, Y Mao, Y Cui, X Fan, L Wen, J Qiao, F Tang Heterogeneity of glial progenitor cells during the neurogenesis-to-gliogenesis switch in the developing human cerebral cortex Cell Reports, 2021-03-02;34(9):108788. 2021-03-02 [PMID: 33657375] (IHC, Human)
• Daniela Regensburger, Clara Tenkerian, Victoria Pürzer, Benjamin Schmid, Thomas Wohlfahrt, Iris Stolzer et al. Matricellular Protein SPARCL1 Regulates Blood Vessel Integrity and Antagonizes Inflammatory Bowel Disease Inflammatory Bowel Diseases 8/19/2021 [PMID: 33393634]
• A Klingler, D Regensburg, C Tenkerian, N Britzen-La, A Hartmann, M Stürzl, E Naschberge Species-, organ- and cell-type-dependent expression of SPARCL1 in human and mouse tissues PLoS ONE, 2020-05-21;15(5):e0233422. 2020-05-21 [PMID: 32437418] (IHC, Human)
• H Hu, W Cai, S Zheng, W Ge SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis Cell. Physiol. Biochem., 2017-12-01;44(4):1485-1496. 2017-12-01 [PMID: 29190626] (IHC, Human)
• Elisabeth Naschberger, Andrea Liebl, Vera S. Schellerer, Manuela Schütz, Nathalie Britzen-Laurent, Patrick Kölbel et al. Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma Journal of Clinical Investigation 10/10/2016 [PMID: 27721236]
• Elisabeth Naschberger, Andrea Liebl, Vera S. Schellerer, Manuela Schütz, Nathalie Britzen-Laurent, Patrick Kölbel et al. Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma Journal of Clinical Investigation 2016-10-10 [PMID: 27721236] (Western Blot, Human)
• Fang Cao, Kuo Wang, Rong Zhu, Yong-Wei Hu, Wen-Zheng Fang, Hou-Zhong Ding Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer Asian Pacific Journal of Cancer Prevention 3/29/2013 [PMID: 23534723]
• Fang Cao, Kuo Wang, Rong Zhu, Yong-Wei Hu, Wen-Zheng Fang, Hou-Zhong Ding Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer Asian Pacific Journal of Cancer Prevention 2013-03-29 [PMID: 23534723] (Western Blot, Human)
• Andrei Turtoi, Davide Musmeci, Antonio Giuseppe Naccarato, Cristian Scatena, Valerio Ortenzi, Robert Kiss et al. Sparc-Like Protein 1 Is a New Marker of Human Glioma Progression Journal of Proteome Research 10/5/2012 [PMID: 22909274]
• Roe O, Szulkin A, Anderssen E, Flatberg A, Sandeck H, Amundsen T, Erlandsen S, Dobra K, Sundstrom S Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma. PLoS ONE, 2012-08-08;7(8):e40521. 2012-08-08 [PMID: 22905093] (IHC-P, Human)
• Li P, Qian J, Yu G, Chen Y, Liu K, Li J, Wang J Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer. J Surg Oncol, 2011-08-30;105(1):31-7. 2011-08-30 [PMID: 22161898] (IHC, Western Blot, Human)

Bioinformatics

• Gene Symbol: SPARCL1
• Uniprot:
  • Q8N4S1()